Emmessar Biotech&Nut
Ticker > Company >

Emmessar Biotech&Nut share price

Emmessar Biotech & Nutrition Ltd.

BSE: 524768 SECTOR: Pharmaceuticals & Drugs  12.63 K   53   2

30.99
+1.24 (4.17%)
BSE: 07 Nov 04:01 PM

Price Summary

Today's High

₹ 31.22

Today's Low

₹ 28.32

52 Week High

₹ 56.33

52 Week Low

₹ 25.8

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 15.48 Cr.

Enterprise Value

₹ 8.61 Cr.

No. of Shares

0.5 Cr.

P/E

38.71

P/B

1.97

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  15.77

CASH

₹ 6.87 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

59.53 %

EPS (TTM)

₹  0.8

Sales Growth

10.03%

ROE

4.19 %

ROCE

12.63%

Profit Growth

-57.82 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.03%
3 Year18.74%
5 Year-29.04%

Profit Growth

1 Year-57.82%
3 Year-12.71%
5 Year-15.95%

ROE%

1 Year4.19%
3 Year7.56%
5 Year11.96%

ROCE %

1 Year12.63%
3 Year13.01%
5 Year20.01%

Debt/Equity

0

Price to Cash Flow

69.18

Interest Cover Ratio

331.4138

CFO/PAT (5 Yr. Avg.)

1.13950414718657

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 59.53 0.00
Jun 2025 59.53 0.00
Mar 2025 59.53 0.00
Dec 2024 59.53 0.00
Sep 2024 59.53 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 18.7402633874066% for the Past 3 years.
  • The company has significantly decreased its debt by 0.1094 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 63.1266 days.
  • Company has a healthy liquidity position with current ratio of 11.3443.
  • The company has a good cash flow management; CFO/PAT stands at 1.13950414718657.
  • The company has a high promoter holding of 59.53%.

 Limitations

  • The company has shown a poor profit growth of -12.7093831027533% for the Past 3 years.
  • Company has a poor ROE of 7.5647% over the past 3 years.
  • The company has a low EBITDA margin of -130.114370661646% over the past 5 years.
  • The company is trading at a high PE of 38.71.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0.08 0.34 0.1 0.1 0.09
Total Expenditure 0.35 0.42 0.38 0.42 0.37
Operating Profit -0.27 -0.08 -0.28 -0.32 -0.28
Other Income 0.46 0.51 0.43 0.61 0.53
Interest 0 0 0 0 0
Depreciation 0.02 0.02 0.02 0.02 0.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.16 0.41 0.13 0.26 0.23
Tax 0.07 0.13 0.11 0.33 0.06
Profit After Tax 0.09 0.28 0.02 -0.07 0.17
Adjusted EPS (Rs) 0.18 0.56 0.04 -0.13 0.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 6.99 0.36 1.02 0.56 0.61
Total Expenditure 6.14 1.26 1.71 1.64 1.56
Operating Profit 0.85 -0.89 -0.69 -1.08 -0.95
Other Income 1.47 1.92 1.75 1.99 2.01
Interest 0 0 0 0 0
Depreciation 0.06 0.09 0.09 0.1 0.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.25 0.93 0.97 0.81 0.96
Tax 0.8 0.46 0.46 0.06 0.64
Net Profit 1.45 0.48 0.5 0.75 0.32
Adjusted EPS (Rs.) 2.9 0.95 1.01 1.5 0.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 5 5 5 5 5
Total Reserves 0.7 1.17 1.67 2.41 2.71
Borrowings 0 0 0 0 0
Other N/C liabilities 0.16 0.44 0.86 0.84 1.04
Current liabilities 1.63 0.99 0.57 0.53 0.67
Total Liabilities 7.49 7.6 8.09 8.77 9.42
Assets
Net Block 1.86 1.46 1.4 1.31 1.22
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.01 0 0 0 0
Other N/C Assets 0 0.62 0.61 0.6 0.59
Current Assets 5.62 5.52 6.08 6.86 7.6
Total Assets 7.49 7.6 8.09 8.77 9.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 2.25 0.93 0.97 0.81 0.96
Adjustment -0.07 -0.13 -0.15 -0.42 -0.37
Changes in Assets & Liabilities -1.61 1.76 -0.5 0.24 -0.35
Tax Paid -0.1 -0.29 0.06 0.02 -0.02
Operating Cash Flow 0.47 2.27 0.38 0.64 0.22
Investing Cash Flow 0.01 -2.61 -0.55 -0.64 -0.23
Financing Cash Flow 0 0 0 0 0
Net Cash Flow 0.48 -0.34 -0.17 0 0

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 59.53 59.53 59.53 59.53 59.53
aman manoj shah 0.33 0.33 0.33 0.33 0.33
amu investment & finance ... 5.20 5.20 5.20 5.20 5.20
amu shares & securities l... - - 0.01 0.01 0.01
appaji venkata krishna mo... 0.10 0.10 0.10 0.10 0.10
arvind moolchand shah 1.33 1.33 1.33 1.33 1.33
arvind moolchand shah (hu... 1.13 1.13 1.13 1.13 1.13
bhavik arvind shah 0.91 0.91 0.91 0.91 0.91
emmessar technologies lim... 21.79 21.79 21.79 21.79 21.79
hema a shah 5.37 5.37 5.37 5.37 5.37
jyothi satyanarayana mall... 0.76 0.76 0.76 0.76 0.76
m s raghavan 5.68 5.68 5.68 5.68 5.68
manar leasing & investmen... 10.57 10.57 10.57 10.57 10.57
prabha vijaykumar agarwal... 0.29 0.29 0.29 0.29 0.29
rajalakshmi raghavan 3.41 3.41 3.41 3.41 3.41
sarada srinivasa raghavan... - - - - 0.52
satyanarayana malla 0.37 0.37 0.37 0.37 0.37
vasudevan raghavan 0.07 0.07 0.07 0.07 0.07
vijay kumar makarla 0.10 0.10 0.10 0.10 0.10
vijaykumar raghunandanpra... 1.59 1.59 1.59 1.59 1.59
sarada srinivasa raghavan... 0.52 0.52 0.52 0.52 -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 40.47 40.47 40.47 40.47 40.47
sandeep rao - 1.99 2.04 2.04 2.04
llp - - 0.15 - -
sandeep rao 1.92 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Emmessar Biotech&Nut - Quaterly Results 7 Aug, 2:12 PM Emmessar Biotech&Nut - Quaterly Results 7 Aug, 2:12 PM Emmessar Biotech&Nut - Quaterly Results 7 Aug, 2:12 PM Emmessar Biotech & Nutrition informs about board meeting 2 Aug, 2:39 PM Emmessar Biotech & Nutrition informs about outcome of board meeting 24 Apr, 5:04 PM Emmessar Biotech&Nut - Quaterly Results 24 Apr, 3:42 PM Emmessar Biotech&Nut - Quaterly Results 24 Apr, 3:42 PM Emmessar Biotech&Nut - Quaterly Results 24 Apr, 3:42 PM Emmessar Biotech&Nut - Quaterly Results 6 Feb, 1:50 PM Emmessar Biotech&Nut - Quaterly Results 6 Feb, 1:50 PM Emmessar Biotech&Nut - Quaterly Results 6 Feb, 1:50 PM Emmessar Biotech & Nutrition submits board meeting intimation 28 Jan, 5:14 PM Emmessar Biotech&Nut - Quaterly Results 7 Nov, 2:24 PM Emmessar Biotech&Nut - Quaterly Results 7 Nov, 2:24 PM Emmessar Biotech&Nut - Quaterly Results 7 Nov, 2:24 PM Emmessar Biotech & Nutrition informs about board meeting 25 Oct, 5:10 PM Emmessar Biotech & Nutrition informs about scrutinizers report 28 Sep, 3:27 PM Emmessar Biotech & Nutrition informs about newspaper advertisements 5 Sep, 5:32 PM Emmessar Biotech & Nutrition informs about newspaper advertisements 5 Sep, 3:47 PM Emmessar Biotech & Nutrition informs about press release 29 Aug, 4:24 PM Emmessar Biotech&Nut - Quaterly Results 14 Aug, 1:48 PM Emmessar Biotech & Nutrition informs about trading window closure 27 Mar, 2:59 PM Emmessar Biotech & Nutrition informs about board meeting 27 Feb, 12:18 PM Emmessar Biotech&Nut - Quaterly Results 3 Feb, 1:27 PM Emmessar Biotech&Nut - Quaterly Results 3 Feb, 1:27 PM Emmessar Biotech&Nut - Quaterly Results 3 Feb, 1:27 PM Emmessar Biotech & Nutrition informs about newspaper clippings 27 Jan, 11:48 AM Emmessar Biotech & Nutrition informs about board meeting outcome 9 Dec, 2:45 PM Emmessar Biotech&Nut - Quaterly Results 9 Dec, 1:47 PM Emmessar Biotech&Nut - Quaterly Results 9 Dec, 1:47 PM Emmessar Biotech&Nut - Quaterly Results 9 Dec, 1:47 PM Emmessar Biotech & Nutrition informs about outcome of EGM 24 Nov, 2:52 PM Emmessar Biotech & Nutrition informs about trading window closure 28 Sep, 1:44 PM Emmessar Biotech & Nutrition informs about disclosure 18 Sep, 11:57 AM Emmessar Biotech & Nutrition informs about disclosure 4 Sep, 1:06 PM Emmessar Biotech & Nutrition informs about press release 28 Aug, 3:09 PM Emmessar Biotech & Nutrition informs about newspaper clippings 13 Jul, 3:11 PM Emmessar Biotech & Nutrition informs about disclosure 1 Jul, 12:24 PM Emmessar Biotech & Nutrition informs about demise of director 22 Jun, 2:15 PM Emmessar Biotech&Nut - Quaterly Results 20 May, 5:04 PM Emmessar Biotech & Nutrition informs about compliances-certificate 6 Apr, 4:37 PM Emmessar Biotech & Nutrition informs about disclosure 23 Mar, 2:39 PM Emmessar Biotech & Nutrition informs about disclosure 14 Mar, 2:21 PM Emmessar Biotech&Nut - Quaterly Results 4 Feb, 4:47 PM Emmessar Biotech&Nut - Quaterly Results 4 Feb, 4:47 PM Emmessar Biotech&Nut - Quaterly Results 4 Feb, 4:47 PM Emmessar Biotech & Nutrition informs about disclosure 26 Dec, 12:56 PM Emmessar Biotech & Nutrition informs about disclosure 24 Nov, 2:34 PM Emmessar Biotech&Nut - Quaterly Results 20 Oct, 5:34 PM Emmessar Biotech&Nut - Quaterly Results 20 Oct, 5:34 PM

Emmessar Biotech&Nut Stock Price Analysis and Quick Research Report. Is Emmessar Biotech&Nut an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Emmessar Biotech&Nut. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Emmessar Biotech&Nut has a PE ratio of 38.7084686485136 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Emmessar Biotech&Nut has ROA of 3.4773% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Emmessar Biotech&Nut has a Current ratio of 11.3443.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Emmessar Biotech&Nut has a ROE of 4.1852%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Emmessar Biotech&Nut has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Emmessar Biotech&Nut has reported revenue growth of 10.0324% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Emmessar Biotech&Nut for the current financial year is -155.508266492061%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Emmessar Biotech&Nut is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Emmessar Biotech&Nut is Rs 0.8006. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Emmessar Biotech&Nut in Ticker for free. Also, one can get the intrinsic value of Emmessar Biotech&Nut by using Valuation Calculators, which are available with a Finology ONE subscription. 

Emmessar Biotech&Nut FAQs

Q1. What is Emmessar Biotech&Nut share price today?
Ans: The current share price of Emmessar Biotech&Nut is Rs 30.99.

Q2. What is the market capitalisation of Emmessar Biotech&Nut?
Ans: Emmessar Biotech&Nut has a market capitalisation of Rs 15.4829139 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Emmessar Biotech&Nut?
Ans: The PE ratio of Emmessar Biotech&Nut is 38.7084686485136 and the P/B ratio of Emmessar Biotech&Nut is 1.96506134872071, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Emmessar Biotech&Nut share?
Ans: The 52-week high share price of Emmessar Biotech&Nut is Rs 56.33, and the 52-week low share price of Emmessar Biotech&Nut is Rs 25.8.

Q5. Does Emmessar Biotech&Nut pay dividends?
Ans: Currently, Emmessar Biotech&Nut does not pay dividends. Dividend yield of Emmessar Biotech&Nut is around 0%.

Q6. What are the face value and book value of Emmessar Biotech&Nut shares?
Ans: The face value of Emmessar Biotech&Nut shares is Rs 10, while the book value per share of Emmessar Biotech&Nut is around Rs 15.7705. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Emmessar Biotech&Nut?
Ans: Emmessar Biotech&Nut has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Emmessar Biotech&Nut?
Ans: The ROE of Emmessar Biotech&Nut is 4.1852% and ROCE of Emmessar Biotech&Nut is 12.6295%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Emmessar Biotech&Nut a good buy for the long term?
Ans: The Emmessar Biotech&Nut long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Emmessar Biotech&Nut undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Emmessar Biotech&Nut appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Emmessar Biotech&Nut’s financials?
Ans: You can review Emmessar Biotech&Nut’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Emmessar Biotech&Nut
X